Xvivo Perfusion: And the beat goes on - Redeye
Bildkälla: Stockfoto

Xvivo Perfusion: And the beat goes on - Redeye

Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments. We see a doubling potential in the share for this emerging niche leader in the coming 12 months, driven by strengthening sentiment and several near-term catalysts.

Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments. We see a doubling potential in the share for this emerging niche leader in the coming 12 months, driven by strengthening sentiment and several near-term catalysts.
Börsvärldens nyhetsbrev